We evaluated 70 HIV-infected pregnant women with CD4+ cell count > 350/ mm who received zidovudine, lamivudine and nevirapine from week 25 of gestation until 6 months after delivery, and a three-week trial of zidovudine and lamivudine at the moment of drug discontinuation. Forty days after the interruption of all drugs resistance mutations were present in 5 out of 70 (7.1%) women. Two of them had the same mutation archived in baseline HIV-DNA. The other 3 women had, at least once, detectable viral load and presence of mutations during treatment. Overall, the risk of developing resistance mutations in compliant women was low.
Palombi, L., Luhanga, R., Galluzzo, C., Andreotti, M., Liotta, G., Ceffa, S., et al. (2011). Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 57(4), 301-304 [10.1097/QAI.0b013e318220ed92].
Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV
PALOMBI, LEONARDO;LIOTTA, GIUSEPPE;
2011-01-01
Abstract
We evaluated 70 HIV-infected pregnant women with CD4+ cell count > 350/ mm who received zidovudine, lamivudine and nevirapine from week 25 of gestation until 6 months after delivery, and a three-week trial of zidovudine and lamivudine at the moment of drug discontinuation. Forty days after the interruption of all drugs resistance mutations were present in 5 out of 70 (7.1%) women. Two of them had the same mutation archived in baseline HIV-DNA. The other 3 women had, at least once, detectable viral load and presence of mutations during treatment. Overall, the risk of developing resistance mutations in compliant women was low.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
